Brief: Natera Q2 Net Income USD -100.9 Million

Natera

07/08/2025 21:22

Overview

Natera Q2 2025 revenue rises 32.2% yr/yr to $546.6 mln

Company raises 2025 annual revenue outlook by $80 mln at midpoint

Net loss widens to $100.9 mln in the qtr

Outlook

Natera raises 2025 revenue outlook to $2.02 bln - $2.10 bln

Company expects 2025 gross margin of 61% to 64%

Natera anticipates positive net cash inflow in 2025

Result Drivers

REVENUE GROWTH - Driven by increased product revenues and higher average selling prices

TEST VOLUME - Processed 12.2% more tests, including a 50.6% increase in oncology tests

GROSS MARGIN - Improved due to reduced costs and higher cash receipts

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
$546.60 mln
Q2 EPS
-$0.74
Q2 Net Income
-$100.90 mln
Q2 Income from Operations
-$110.40 mln
Q2 Operating Expenses
$457 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for Natera Inc is $197.50, about 30.1% above its August 6 closing price of $138.13

Press Release: ID:nBw9K5ZdKa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)